Aldeyra Therapeutics forays into agreement with Johnson and Johnson

Aldeyra Therapeutics enters into a collaborative research agreement with Janssen Research and Development, LLC which is ideally one of the Janssen Pharmaceutical Companies of Johnson and Johnson.

The collaboration is in line with the development of novel drugs designed to sequester pro-inflammatory aldehyde mediators which is a new class of therapeutic targets. Aldeyra’s adehyde sequestration platform represents a novel therapeutic class which is led by reproxalap. The agreement is primarily to advance the development of existing analogs of reproxalap for the treatment of systemic inflammatory diseases.

Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra said “As we are committed to the development of novel therapeutic product candidates for autoimmune and other diseases characterized by systemic inflammation, we are pleased to partner with Janssen, a world leader in the discovery and development of therapeutics for inflammatory diseases.”